Nina Capital led the seed follow on round to support international growth and product scaling.
"Today’s seed funding exceeded our initial ask, showing the excitement building around Zetta Genomics’ game changing XetaBase data analytics platform. We now have the strategic headroom to configure for growth – to scale our technologies, enhance customer focus, and create a cycle of ongoing product innovation. This investment sees us one step closer to realising predictive, precision genomics – transforming research, healthcare and the lives of millions."
The seed round was led by Aleph and 83 North to back the smart business account provider.
"The community of e-commerce entrepreneurs deserves better than they’re getting today. We want to give SME leaders the tools they need to grow their businesses with confidence. By providing a seamless financial management solution, we help SMEs overcome their daily challenges while unlocking opportunities to set themselves up for long-term growth. They can better serve their international customers, employees, and providers, and ultimately create more value for their businesses,"
The financing round was led by Oxford Science Enterprises and will support market expansion in the UK, EU, and United States.
"We are thrilled that five successful institutional investors participated in the financing round which validates the vast clinical and business potential of Caristo’s innovations"
The investment round was co-led by Aviva Ventures, YZR Capital, Oxford Capital, Triple Point Ventures and Simplyhealth Ventures to fund US expansion and new product development.
"Our investment in Scan.com is a statement of our intent to invest in promising young digital and tech firms – they are growing rapidly, have a unique customer proposition and are already leading the way on medical imaging services in the UK. We are really excited to support Scan.com’s development and growth."
Octopus Ventures led the financing round, which will fund technology development and team expansion.
"People who survive their cancers feel lost in transition. They can’t get the care they need, find the healthcare system confusing and uncoordinated, and continue to suffer with the late and long-term effects of curative cancer treatments. At Perci, with our growing team of specialists, we’re on a mission to change that."
